Oncology & Cancer

Imaging of pelvis has limited value in hepatocellular cancer

(HealthDay)—For patients with a primary diagnosis of hepatocellular cancer (HCC), imaging of the pelvis rarely provides additional pathologic information, according to a study published online June 14 in the Journal of ...

Oncology & Cancer

Dual-agent PET/MR with time of flight detects more cancer

Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) followed by quantitative scanning significantly improves image quality and detection of bone metastases ...

Oncology & Cancer

Zoledronic acid every 12 weeks noninferior in bone metastases

(HealthDay)—Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple ...

Oncology & Cancer

Tasquinimod improves radiographic PFS in mCRPC

(HealthDay)—For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study ...

Oncology & Cancer

Predicting advanced prostate cancer outcomes with NaF-PET/CT

A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients ...

Oncology & Cancer

ASCO: Cabozantinib improves progression-free survival in RCC

(HealthDay)—For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled ...

page 2 from 7